

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1.-4 (Cancelled)
5. (Withdrawn)
6. (Withdrawn)
7. -8 (Cancelled)
9. (Currently amended) A method ~~Method~~ of treating a CD137 expressing tumor in a patient comprising administering to a patient in need thereof an effective amount of a CD137 antagonist.
10. (Currently Amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is ~~selected from the group consisting of~~ a CD137-specific antibody, a peptide, an organic small molecule, an antisense oligonucleotide, a siRNA, an antisense expression vector or a recombinant virus.
11. (Currently Amended) A method ~~Method~~ according to claim 9 wherein the tumor is a B cell lymphoma, a tumor of the vulva, a neuroblastoma, a cystadenocarcinoma of the ovary, a rhabdomyosarcoma, a leiomyosarcoma, a fibrosarcoma, an immunocytoma, a non-Hodgkin lymphoma, a carcinoma of the portio uteri or a basal cell carcinoma.
12. (Currently amended) A method ~~Method~~ according to claim 11 wherein the B cell lymphoma is chronic lymphocytic leukemia ~~leukaemia~~.
13. (Withdrawn-Currently Amended) ~~Use of CD137 or a functional analogue or derivative thereof for the preparation of a medicament~~ A method for the

treatment of ~~conditions~~ a condition characterised by undesired or overactive immune responses comprising administering to a patient having a condition characterised by undesired or overactive immune response a therapeutically effective amount of a medicament comprising CD137 or a functional analogue or derivative thereof.

14. (Withdrawn-Currently Amended) Use A method according to claim 13 wherein the CD137 or functional analogue or derivative is encoded by a nucleic acid comprising a nucleotide sequence having at least 90% homology to the coding sequence shown in ~~Fig. 8A~~ SEQ. ID No. 1.
15. (Withdrawn-Currently amended) Use A method according to claim 14 wherein the CD137 has the amino acid sequence shown in ~~Fig. 8B~~ SEQ. ID No. 2.
16. (Withdrawn-Currently Amended) Use A method according to claim 13 wherein the condition is ~~selected from an~~ autoimmune disease, an allergy, ~~diseases, allergies, asthma and or an~~ organ transplant rejection.
17. (Withdrawn-Currently Amended) Use A method ~~of an agonistic anti-CD137 ligand antibody~~ for the preparation of a medicament for the treatment of ~~conditions~~ a condition characterised by an undesired or overactive immune response ~~responses comprising admixing an agonistic anti-CD137 ligand antibody with a pharmaceutically acceptable carrier.~~
18. (Withdrawn-Currently Amended) Use A method according to claim 17 wherein the condition is ~~selected from autoimmune diseases, allergies, asthma and organ transplant rejection~~ an autoimmune disease, an allergy, asthma or an organ transplant rejection.

19. (Withdrawn-Currently Amended) A method ~~Method~~ for treating a patient suffering from a condition characterised by an undesired or overactive immune ~~responses~~ response comprising administering an effective amount of CD137 or a functional analogue or derivative thereof and/or an agonistic anti-CD137 ligand antibody.
20. (Withdrawn-Currently Amended) A method ~~Method~~ of claim 19 wherein the CD137 or functional analogue or derivative thereof is encoded by a nucleic acid comprising a nucleotide sequence having at least 90% homology to the coding sequence shown in ~~Fig. 8A~~ SEQ. ID No. 1.
21. (Withdrawn-Currently Amended) A method ~~Method~~ of claim 19 wherein the condition is ~~selected from~~ an autoimmune disease ~~diseases~~, an allergy ~~allergies~~, asthma ~~and~~ or an organ transplant rejection.
22. (Currently amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is an antibody directed to at least one epitope of the amino acid sequence of human CD137 shown in ~~Fig. 8B~~ SEQ. ID No. 2.
23. (Currently amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is clone BBK- 2 or clone 4B4-1
24. (Withdrawn-Currently Amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is the antisense expression vector RSV-ILA-AS.
25. (Withdrawn-Currently Amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is ~~selected from the group consisting of~~ a CD137 ligand-specific antibody, a peptide, an organic small molecule, an antisense

oligonucleotide, a siRNA, an antisense expression vector or a recombinant virus.

26. (Withdrawn-Currently Amended) A method ~~Method~~ of claim 20 wherein the CD137 has the amino acid sequence shown in ~~Fig. 8B~~ SEQ. ID No. 2.